VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Virax Biolabs Group Ltd
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026
$1.40−0.05 (-3.45%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Virax Biolabs has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Virax Biolabs filed with the SEC
(Incorporated under the laws of the Cayman Islands)
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
(adopted by special resolution passed on [Date])
EX-99.3 to Form 6-K
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
EX-99.1 to Form 6-K
(Incorporated under the laws of the Cayman Islands)
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
(adopted by special resolution passed on [Date] and effective on [Date])
EX-99.3 to Form 6-K
(Incorporated under the laws of the Cayman Islands)
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
Virax Biolabs Group Limited Announces $5 Million Private Placement
EX-99.1 to Form 6-K
Virax Biolabs to Present at 19th World Immune Regulation Meeting
EX-99.1 to Form 6-K
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
EX-99.1 to Form 6-K
(Incorporated in the Cayman Islands with limited liability)
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
Virax Biolabs Group Limited to Participate at ESCMID Global 2024
EX-99.1 to Form 6-K